Experts share their thoughts on the link between these respiratory conditions and what it means for treatment. Nasal polyps are small, noncancerous growths that develop inside the nasal canal. They ...

Surgery precedes biologics but comes after saline irrigations and topical intranasal corticosteroids in a new treatment algorithm for US clinicians treating patients who have chronic rhinosinusitis ...

For some people, nasal polyps in the nose or sinuses are small and painless, but for others, the growths may be large enough to cause more serious symptoms — not just congestion and a runny nose but ...

Although nasal polyps are noncancerous, these soft growths in the lining of your sinuses or nasal passages can worsen if your body's inflammation levels rise. That can lead to uncomfortable symptoms ...

Treating nasal polyps isn’t a one-and-done procedure. The complications from these growths, which develop in the lining of ...

Nasal polyps are painless, teardrop-shaped growths that form in your nose or sinuses. They’re most common where the sinuses near your eyes and cheekbones drain into your nose. Nasal polyps are not ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...

Xhance (fluticasone propionate) is a prescription drug that’s used to treat chronic sinusitis. Xhance comes as a nasal spray. Xhance is used in adults to treat chronic (ongoing) sinusitis (sinus ...

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. "Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment," at 4:21 p.m. ET, ...